Pharmaceutical firm GlaxoSmithKline (GSK) announced Tuesday it received approval from the Food and Drug Administration (FDA) ...

Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.

First you’ll need to log back into 23andMe, if you can remember your details that is. Then you can submit the deletion ...

Research Triangle Park (RTP) in North Carolina is now one of the world’s top spots for innovation, but it didn’t start out ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...

Artificial intelligence chatbots cannot be relied on to give accurate, safe or even clear advice about medication, according ...

Locally advanced cervical cancer remains a substantial source of mortality, particularly in low-resource settings.1 ...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

The global generic oncology drugs market is projected to grow at a 6% CAGR from 2022 to 2028, reaching over USD 34.8 billion ...

UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...